Last reviewed · How we verify
NCT05920499
The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage
NA trial testing AUDIT and Feedback in Pneumococcal Infections in 36 participants. Not yet recruiting.
31 January 2026
Quick facts
| Lead sponsor | Bert Vaes |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 36 |
| Start date | 31 January 2025 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- AUDIT and Feedback
Conditions studied
- Pneumococcal Infections — all drugs for Pneumococcal Infections →
Sponsor
Bert Vaes
Who can join
Adults 16 to 85, any sex, with Pneumococcal Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this cluster-randomized trial is to study the effect of Audit and Feedback loops on pneumococcal vaccination coverage rate in adults at risk in general practice. The main questions it aims to answer are: * To assess the effect of "clinical AUDIT and feedback" loops on the pneumococcal vaccination coverage rate in adults at risk in general practice. * To explore whether the increase in vaccination coverage rate after implementation of Audit and Feedback loops is different in specific subgroups (risk groups, male/female, age, smoking status). Every general practice center assigned to the control or intervention group will have access to a clinical AUDIT to identify patients that may benefit from a pneumococcal vaccination. The general practice centers in the intervention group will also receive an individualized extended electronic feedback report, with multiple components like benchmarked performances and action plans, at baseline and each 2 months from baseline onwards.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05920499
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pneumococcal Infections
Currently open trials in the same condition.
- NCT06822907 — Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults · Phase 4 · recruiting
- NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
- NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
- NCT06608199 — A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 · Phase 3 · recruiting
- NCT04945681 — Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05920499 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bert Vaes
- Last refreshed: 24 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05920499.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing